Otsuka's 24-Month Kidney Data Could Reshape VOYXACT-The Real-World Test Comes Next

Why the 24-month VISIONARY data matter for VOYXACT

Otsuka's 4.5 mL/min/1.73 m²/year advantage in kidney-function decline over two years is clinically meaningful. In IgA nephropathy, that kind of separation can strengthen VOYXACT's role beyond a niche option.

The timing matters because the full 24-month VISIONARY results were released earlier this month and presented at GlomCon Hawaii 2026 this week. For Otsuka, this is now more than a strong trial headline: it is a live regulatory milestone. The data also support VOYXACT's potential to preserve long-term kidney function, which is central to the drug's value proposition for clinicians, patients, and payers.

The key question is no longer only whether VOYXACT shows benefit. It is whether the traditional-approval story adds enough to the existing narrative to matter for the franchise going forward.

What the eGFR results show

The two-year difference is large and consistent

eGFR is the kidney-function measure clinicians rely on most. In simple terms, a faster drop means faster loss of function. VOYXACT's 24-month data showed +0.3 vs. -4.2 mL/min/1.73 m²/year for sibeprenlimab versus placebo. Otsuka described that outcome as returning kidney-function decline to something closer to a baseline physiologic rate.

That matters because the benefit was not delayed. At 12 months, VOYXACT already showed a change from baseline of +0.7 versus -4.8 with placebo. The later 24-month results kept the same direction of benefit and expanded the gap, which argues against the idea that the effect only appeared late in the trial.

Why clinicians and payers should care

For nephrologists, the signal is practical: VOYXACT is a selective APRIL inhibitor, and in this trial it stabilized kidney function over two years rather than producing only a short-lived lab change. In chronic kidney disease, durability is part of therapeutic value.

For payers, stable kidney function is also a useful endpoint because it tracks with outcomes patients care about. The 24-month eGFR results are supporting Otsuka's supplemental Biologics License Application for traditional approval. If that path succeeds, VOYXACT could broaden from an approved option into a more central part of IgA nephropathy treatment.

What still has to be proven

The clinical case is strong, but the next test is real-world adoption. Approval and reimbursement still need to reflect the size of the kidney-function benefit, and payers will want to see that the trial results translate into practical value across broader patient populations.

For Otsuka, that is the next milestone: moving from a compelling two-year eGFR signal to durable prescribing, coverage, and franchise growth.